Suraksha Diagnostic Limited (SURAKSHA)

Small Cap

Pharma stocks · Small cap · NSE

Suraksha Diagnostic Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.

₹297.95

-8.75 · -2.85%

Market cap ₹1,728 Cr

ThemesPharma Healthcare & Hospitals Medical Devices & Diagnostics

Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm IST

Details

Quote19 Oct, 03:31 pm IST

Base fundamentals06 Oct 2026 · screener

Latest result12 Aug, 05:54 pm IST

Score20 Oct, 04:30 am IST · v4.3-runtime-valuation

Tags04 Oct 2026

Coverage14/14 · 100%

Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)

Technical timing lens

Trend score and candlestick chart

68Bullish

MACD − · sector +3.8pp vs Nifty 500 (3M)

Stock trend: 47

Sector RS: 98

Sector 3M: -1.8% vs Nifty 500 -5.6%

Pharma FPI tailwindFlow only

FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence

Compare peers →

Technical chart

SURAKSHAD candles · FIT view+5.5%

Latest close ₹297.95 on 2026-10-19

Bar

-3.0%

RSI

MACD hist

-4.84

52W pos

54%

2026-10-19O ₹307.10H ₹308.80L ₹295.05C ₹297.95Vol 31,616 sh

Up bar

Down bar

EMA 20

EMA 50

Volume + 20D avg

Result date

RSI(14)

MACD / signal

Market context

Relative performance and chart statistics

Adjusted completed-session prices, rebased to 100

SURAKSHANifty PharmaNifty 500

SURAKSHA: +15.4%
Nifty 500: -5.6%
Nifty Pharma: -1.5%
Vs Nifty 500: +21.0 pp

Chart stats

19 Oct 2026

From 52W high: -17.2%
52W range position: 54%
ATR (14): 5.4%
Volume vs 20D: 0.40x
Avg traded value: ₹2.5 Cr
20D price channel: ₹295.1 - ₹360

Quarter ended 30 Jun 2026

Excellent · 100

Rev +21% YoY · PAT +44% YoY · margin expansion · +9% QoQ · operating leverage

Revenue: ₹88 Cr; YoY +20.6%
PAT: ₹13 Cr; YoY +44.4%
Operating margin: 35.0%; QoQ +500 bps
PAT margin: 14.8%; QoQ +736 bps

Filed 12 Aug 2026Full result & history →

Current-quarter concall

Transcript not linked yet

No source-linked earnings-call transcript is available for this company in the active results quarter.

Search Concall Intelligence

Technical snapshot

Positioning and participation

Stage 2 Uptrend

Current trend context ranked against all active NSE stocks. It describes the chart; it is not a buy or sell signal.

RS percentile: 65; -8 ranks over 20D
Stage 2 entry: 31 Aug 2026; 34 trading sessions · established
Sector rotation: #1; leading · 198 stocks
Industry rotation: #17; leading · 81 stocks

Trend structure

Below 20-DMABelow 50-DMAAbove 200-DMA

RSI (14)

Weak momentum

MACD

Below signal

Histogram -4.84

Volume participation

0.4x average

Versus 20-session average

20-session position

4% of range

₹295.05 low · ₹360 high

Relative performance

vs Nifty 500

1M: -7.6 pp; stock -11.1%
3M: +21.0 pp; stock +15.4%
6M: +9.6 pp; stock +6.0%
1Y: +5.9 pp; stock -1.1%

From 52W high

-17.2%

High ₹360

52W range position

54%

₹224.1 - ₹360

ATR (14)

5.4%

₹16.11

Avg traded value

₹2.5 Cr

20-session average

Current setup

Established Stage 2

Entered 31 Aug 2026 · 34 sessions

Open detailed technicals →

Research snapshot

What the evidence says now

Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.

Weak U-Score but strong trend: momentum may be ahead of fundamentals.

Suggested next step

Momentum only

Trend is strong but fundamentals do not support a clean investment thesis.

U-Score

Legacy · FAIR VALUE

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Financials

Fundamentals, quarterly history, margins, returns and balance-sheet evidence

Quarter ended 30 Jun 2026

Excellent · 100/100

Rev +21% YoY · PAT +44% YoY · margin expansion · +9% QoQ · operating leverage

Filed 12 Aug 2026

Open results browser →

Metric	This quarter	YoY	QoQ
Revenue	₹88 Cr	+20.6%	+8.6%
EBITDA	₹30 Cr	+25.0%	+25.0%
Operating margin	35.0%	+200 bps	+500 bps
PAT	₹13 Cr	+44.4%	+116.7%
PAT margin	14.8%	+244 bps	+736 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Fundamentals

Valuation

P/E: 48.30
P/B: 7.06
EV/EBITDA: 12.81
Market Cap: 1728.00Cr

Profitability

ROE: 14.20%
ROCE: 17.30%
ROA: 7.81%
Dividend Y: 0.15%

Growth (CAGR)

Revenue 5Y: 17.00%
EPS 5Y: 32.00%
Revenue 3Y: 18.00%
EPS 3Y: 62.00%

Balance Sheet

Debt/Equity: 0.53
Interest Coverage: 7.29×
Altman Z: 7.49
Book Value: 47.00

Cash Flow

FCF Yield: 1.74%
FCF Positive Y: 5/5
OCF: 82.00 Cr
EPS TTM: 6.88

Shareholding

Promoter Hold: 49.10%
Promoter Pledge: 0.00%
Momentum 52W: 79%

Financial History

Updated 20/10/2026

Revenue

₹ Cr

Latest: 88.0+8.6% vs prev

Net Profit

₹ Cr

Latest: 13.0+116.7% vs prev

ROE is shown only in the Annual view — quarterly equity data isn't published.

Technicals

Trend interpretation, Stage 2, relative strength, volume and indicator evidence

Daily technical trend read

Neutral

Trend is undirectional — long-term uptrend intact. RSI 35.

Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
SMA20 roughly flat — short-term momentum stalled.
RSI(14) at 35 — falling, no extreme reading.
MACD below signal but histogram contracting — bearish momentum easing.
17% off 52W high · 33% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Nifty 500 leadership

Relative Strength & Trend Stage

RS percentile

Stage 2 UptrendEstablished S2

1M return

-11.1%

3M return

+15.4%

6M return

+4.7%

1Y return

-7.7%

RS 1D

-1

RS 20D

-8

Sector rank

Industry rank

#17

Stage evidence

Price is 3.1% above the 30-week proxy.
The 50-DMA is above the 30-week proxy and its slope is rising +3.1%.
Both 3-month and 6-month returns are positive.

50-DMA

price below

200-DMA

price above

S2 entered

31 Aug 2026

S2 age

34 trading sessions

Sector

leading

Industry

leading

Relative-strength line vs Nifty 500 (base 100)

262 observations

19 Oct 2026Value 103.03-1.85%

RS vs Nifty 500103

Valuation & peers

U-Score 52 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies

Financial Turnaround

Fundamental score breakdown

U band · FAIR VALUE

Valuation3/30

Growth21/25

Quality9/20

Balance Sheet7/15

Cash Flow7/10

Piotroski

8/9 (+5)

Penalties

Raw sum

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

52/100 · legacy band FAIR VALUE

Positive drivers

Piotroski is strong at 8/9.
Growth contributes 21/25 to the score.
Cash flow contributes 7/10 to the score.

Main drags

Valuation is weaker at 3/30; verify the latest quarterly trend.
Quality is weaker at 9/20; verify the latest quarterly trend.
Balance sheet is weaker at 7/15; verify the latest quarterly trend.

Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA

Primary lens

PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.

Secondary checks

USFDA risk, launch pipeline, margin trend, domestic vs export mix.

Main risk check

Regulatory setbacks or one-off product cycles can distort valuation.

48.3

7.1

EV/EBITDA

12.8

ROE

14.2%

ROCE

17.3%

FCF Yield

1.7%

Debt/Equity

0.5

MoS

+3.8%

Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 20 Oct 2026

v4.3-runtime-valuation

Final score

Previous: 52

Legacy U-Score band

FAIR VALUE

Previous: FAIR VALUE

Margin of safety

+3.8%

Previous: +3.8%

Score history

12 stored score snapshots. Latest stored move: +0 points.

20 Oct 2026

v4.3-runtime-valuation

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.

Modelled fair value

Graham Number

₹85.3

-249.3% MoS

Growth-justified P/E

45.0

Growth-justified Value

₹309.6

+3.8% MoS

PEG

1.10

Comparable companies

Peers

Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.

Compare all ↗

Ticker

Name

Why peer

Score

ROE

MoS

Verdict

KRSNAA

Small

Krsnaa Diagnostics Limited

TTK Healthcare Limited

Syncom Formulations (India) Limited

Lincoln Pharmaceuticals Limited

Sakar Healthcare Limited

Business, management & trust

Growth engines, risks, management commitments and evidence-backed delivery

Business and thesis

Issuer presentation review pending

Suraksha Diagnostic Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.

Trust Score

75Limited evidence · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Limited evidence: Claim history is still being built. It ranks around the 78th percentile of the scored universe and 69th percentile within Pharma. No major sub-score weakness stands out.

This is a financial-behaviour screen, not a claim-tested management reliability verdict.

Computed 05 Sept 2026

management-trust-v1

31 docs text-extracted · 14 concalls text-extracted

Score band

Limited evidence

Financial behaviour is scored, but management claims do not yet have enough outcome checks.

Relative rank

78th percentile

overall median 67 · Pharma: 69th pctile, median 70 · Small: 80th pctile, median 66

Evidence depth

Financial-only

31 documents have extracted text, but claim history is not strong enough yet.

Claim delivery

Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Limited evidence · low confidence

What it measures

Reliability of management and financial delivery, using financial behaviour only.

Confidence

Treat this as an early read until more concalls and outcomes are matched.

Investor use

Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter

strong · holding, pledge, alignment

Cash flow

strong · profit to cash conversion

Balance sheet

strong · leverage and solvency

Discipline

acceptable · capital discipline

Results

acceptable · quarterly consistency

Trust positives

▸Promoter pledge is zero.
▸FCF yield is positive at 1.7%.
▸5 years of positive FCF.
▸4/4 latest quarters had positive YoY revenue growth.

Trust risks

▸No major Trust Lite risk flags.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Compare Pharma stocks Browse Indian stocks starting with S Explore fundamental stock screeners Browse Indian investment themes

Related companies

Krsnaa Diagnostics Limited (KRSNAA)TTK Healthcare Limited (TTKHLTCARE)Syncom Formulations (India) Limited (SYNCOMF)Lincoln Pharmaceuticals Limited (LINCOLN)Sakar Healthcare Limited (SAKAR)

Important announcements & filings

Latest exchange and company disclosures found within the past two years.

Source: Bse

Open source ↗

Verify on:NSE India ↗

All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.

Suraksha Diagnostic Limited (SURAKSHA)

Trend score and candlestick chart

Technical chart

Relative performance and chart statistics

What the evidence says now

Financials

Quarter ended 30 Jun 2026

Fundamentals

Valuation

Profitability

Growth (CAGR)

Balance Sheet

Cash Flow

Shareholding

Revenue

Net Profit

Technicals

Daily technical trend read

Relative Strength & Trend Stage

Valuation & peers

Fundamental score breakdown

Why this score?

Positive drivers

Main drags

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Stored run vs live recompute

Score history

Factor attribution

Modelled fair value

Comparable companies

Business, management & trust

Issuer presentation review pending

How to read this Trust Score

Forensic breakdown

Trust positives

Trust risks

Continue researching Suraksha Diagnostic Limited

Important announcements & filings

Sep 2026 · Intimation Under Regulation 30 And 36(1)(B) Of The SEBI (LODR) Regulations, 2015 (SEBI Listing Regulations) 27 Aug - 21st AGM on 22 September 2026; annual report sent, dividend record date 15 September 2026.

Sep 2026 · Notice For The 21St Annual General Meeting (AGM) Of The Company 27 Aug - Annual Report FY2025-26 and notice for 21st AGM on 22 September 2026 released.

Aug 2026 · Transcript

Aug 2026 · PPT

Aug 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Aug - The Newspaper Advertisement published on Monday, 31st August, 2026 with respect to the "Notice of 21st Annual General Meeting and e-voting information."

Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Aug - Newspaper Publication for Notice of the 21st Annual General Meeting(AGM) of the Company

Jul 2026 · Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer 9 Jun - Ms. Mamta Jain resigned as Company Secretary and Compliance Officer; last working day 15 July 2026.

Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Newspaper Publication of unaudited ( Standalone & Consolidated) Financial Results of the Company for the quarter ended 30 June 2026.

Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Aug - Suraksha Diagnostic reported Q1 FY27 results: revenue up 21%, PAT up 40%, and commissioned one hub, three spokes.

May 2026 · PPT

May 2026 · Transcript

May 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 May - Suraksha Diagnostic posted FY26 results on 21 May 2026; total income rose 23% to ₹3,136 million.